Pharma Mar S.A. (PHM) - Total Liabilities
Based on the latest financial reports, Pharma Mar S.A. (PHM) has total liabilities worth €143.25 Million EUR (≈ $167.47 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pharma Mar S.A. - Total Liabilities Trend (2002–2025)
This chart illustrates how Pharma Mar S.A.'s total liabilities have evolved over time, based on quarterly financial data. See Pharma Mar S.A. (PHM) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Pharma Mar S.A. Competitors by Total Liabilities
The table below lists competitors of Pharma Mar S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CLEARWAY ENERGY A NDL-01
F:NY4B
|
Germany | €11.36 Billion |
|
Sunwave Communications Co Ltd
SHE:002115
|
China | CN¥2.47 Billion |
|
Ral Yatirim Holding AS
IS:RALYH
|
Turkey | TL8.18 Billion |
|
Fangda Special Steel Technology Co Ltd
SHG:600507
|
China | CN¥11.72 Billion |
|
Interroll Holding AG
SW:INRN
|
Switzerland | CHF108.31 Million |
|
Arlo Technologies
NYSE:ARLO
|
USA | $200.79 Million |
|
Shanghai Qiangsheng Holding Co Ltd
SHG:600662
|
China | CN¥9.96 Billion |
|
Companhia Siderúrgica Nacional
SA:CSNA3
|
Brazil | R$83.47 Billion |
Liability Composition Analysis (2002–2025)
This chart breaks down Pharma Mar S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Pharma Mar S.A. worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pharma Mar S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pharma Mar S.A. (2002–2025)
The table below shows the annual total liabilities of Pharma Mar S.A. from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €143.25 Million ≈ $167.47 Million |
+1.39% |
| 2024-12-31 | €141.28 Million ≈ $165.18 Million |
-3.94% |
| 2023-12-31 | €147.08 Million ≈ $171.95 Million |
-13.63% |
| 2022-12-31 | €170.30 Million ≈ $199.10 Million |
-10.59% |
| 2021-12-31 | €190.47 Million ≈ $222.68 Million |
-16.29% |
| 2020-12-31 | €227.54 Million ≈ $266.01 Million |
+94.06% |
| 2019-12-31 | €117.25 Million ≈ $137.08 Million |
-16.37% |
| 2018-12-31 | €140.20 Million ≈ $163.91 Million |
-14.89% |
| 2017-12-31 | €164.74 Million ≈ $192.59 Million |
-4.58% |
| 2016-12-31 | €172.64 Million ≈ $201.84 Million |
+24.29% |
| 2015-12-31 | €138.90 Million ≈ $162.39 Million |
-1.71% |
| 2014-12-31 | €141.32 Million ≈ $165.22 Million |
+0.99% |
| 2013-12-31 | €139.94 Million ≈ $163.60 Million |
-13.14% |
| 2012-12-31 | €161.10 Million ≈ $188.35 Million |
-12.12% |
| 2011-12-31 | €183.31 Million ≈ $214.31 Million |
-6.45% |
| 2010-12-31 | €195.96 Million ≈ $229.10 Million |
+15.15% |
| 2009-12-31 | €170.18 Million ≈ $198.96 Million |
+7.57% |
| 2008-12-31 | €158.20 Million ≈ $184.95 Million |
+18.49% |
| 2007-12-31 | €133.51 Million ≈ $156.09 Million |
+13.89% |
| 2006-12-31 | €117.23 Million ≈ $137.06 Million |
+248.07% |
| 2005-12-31 | €33.68 Million ≈ $39.38 Million |
-6.72% |
| 2004-12-31 | €36.11 Million ≈ $42.21 Million |
-73.49% |
| 2003-12-31 | €136.20 Million ≈ $159.23 Million |
+30.29% |
| 2002-12-31 | €104.53 Million ≈ $122.21 Million |
-- |
About Pharma Mar S.A.
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound deri… Read more